The aim of the present study is to evaluate the effectiveness of the addition of the postbiotic Pediococcus acidilactici (pA1c®HI) on amelioration of metabolic disturbances in patients with (FEP) or (SSD) treated with antipsychotic drugs.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Metabolic Disturbances
Timeframe: Beginning (week 0) and end of the study (week 12).
Metabolic Disturbances
Timeframe: Beginning (week 0) and end of the study (week 12)
Metabolic Disturbances
Timeframe: Beginning (week 0) and end of the study (week 12)
Metabolic Disturbances
Timeframe: Beginning (week 0) and end of the study (week 12)
Metabolic Disturbances
Timeframe: Beginning (week 0) and end of the study (week 12)
Metabolic Disturbances
Timeframe: Beginning (week 0) and end of the study (week 12)
Metabolic Disturbances
Timeframe: Beginning (week 0) and end of the study (week 12)
Metabolic Disturbances
Timeframe: Beginning (week 0) and end of the study (week 12)